ChemGenex Of Australia Seeks Capital To Bolster Key Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
Australia's ChemGenex plans to bolster its negotiating position with multinational pharmaceutical companies by raising enough capital to give it leverage in a licensing deal. At stake is ChemGenex's leukemia drug omacetaxine nearing completion of Phase III trials. CEO Greg Collier said the firm's intention is to get as much value for the drug as it can while pursuing licensing deals, negotiations for which he said are going well and would enable ChemGenex to retain some rights. The firm expects to submit its application for U.S. approval by mid-year. (Click here for more
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.